Alembic receives USFDA approval for acyclovir ointment

Alembic Pharma has received USFDA approval for its Acyclovir ointment USP, used for the treatment of genital herpes. The ointment is therapeutically equivalent to the reference listed drug product (RLD) Zovirax ointment 5 per cent of Valeant Pharmaceuticals North America LLC. The drug is used for management of initial genital herpes and in limited non-life-threatening mucocutaneous herpes simplex virus infections in immunocompromised patients. According to IMS data, for the twelve months ending December 2016, the ointment has an estimated market size of $145 million.

Company Profile : Alembic Pharmaceuticals Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*